Zentalis Pharmaceuticals
ZNTL
106 hedge funds and large institutions have $1.29B invested in Zentalis Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 48 increasing their positions, 30 reducing their positions, and 20 closing their positions.
6,496% more call options, than puts
Call options by funds: $1.58M | Put options by funds: $24K
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
60% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 30
9.54% more ownership
Funds ownership: 103.2% → 112.74% (+9.5%)
2% more capital invested
Capital invested by funds: $1.27B → $1.29B (+$27.5M)
12% less funds holding
Funds holding: 120 → 106 (-14)
70% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$65.6M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$19.9M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$10.7M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$9.05M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Axa
Paris,
France
|
-$4.96M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$3.73M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
-$3.68M |
| 4 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$3.44M |
| 5 |
Walleye Capital
New York
|
-$1.85M |
ZNTL Hedge Fund Activity: Q4 2022 in Review
106 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q4 2022, worth a combined $1.29B — up 2.2% from $1.27B a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of ZNTL and 6 opened new positions — a net loss of 14 holders — while 30 trimmed existing stakes and 48 added.
The largest buyer was Capital International Investors, opening a new position worth an estimated $65.6M. The largest seller was Axa, exiting entirely with an estimated $4.96M sold.
- 106 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q4 2022, down from 120 in Q3 2022.
- Funds reported $1.29B of Zentalis Pharmaceuticals stock for Q4 2022, up 2.2% quarter-over-quarter.
- 6 funds opened new Zentalis Pharmaceuticals positions in Q4 2022 and 20 closed out, a net change of -14 holders.
- The largest Zentalis Pharmaceuticals buyer in Q4 2022 was Capital International Investors, an estimated $65.6M added.
- The largest Zentalis Pharmaceuticals seller in Q4 2022 was Axa, an estimated $4.96M sold.
Based on aggregated 13F filings for Q4 2022.